XML 46 R37.htm IDEA: XBRL DOCUMENT v3.8.0.1
Restatement of Financial Statements (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Net sales $ 1,384,429 $ 279,883 $ 4,252,704 $ 845,513
Cost of sales 388,202 73,988 1,268,320 237,707
Gross Profit 996,227 205,895 2,984,384 607,806
Operating expenses        
Compensation and related expenses 361,829 101,137 1,077,340 301,301
Professional fees 82,608 29,237 277,282 91,059
Marketing expenses 554,536 1,713,337
General and administrative expenses 204,958 57,580 382,857 206,841
Total operating expenses 1,203,931 187,954 3,450,816 599,201
Operating Income (Loss) (207,704) 17,941 (466,432) 8,605
Interest (expense) (9,992) (14,422) (15,805) (33,048)
Net Income (Loss) Before Taxes (217,696) 3,519 (482,237) (24,443)
Deferred income tax benefit (4,600) (13,200)
Net Income (Loss) (217,696) 8,119 (482,237) (11,243)
Net income (loss) attributable to noncontrolling interests 8,955 6,439
Net Income (loss) attributable to Immudyne, Inc. $ (226,651) $ 8,119 $ (488,676) $ (11,243)
Basic and diluted (loss) per share attributable to Immudyne, Inc. $ (0.01) $ 0.00 $ (0.02) $ 0.00
Average number of common shares outstanding        
Basic 34,427,087 30,650,000 31,917,873 30,663,306
Diluted $ 34,427,087 $ 30,650,000 $ 31,917,873 $ 30,663,306
As Reported [Member]        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Net sales $ 1,384,429   $ 4,252,704  
Cost of sales 942,738   2,981,657  
Gross Profit 441,691   1,271,047  
Operating expenses        
Compensation and related expenses 361,829   1,077,340  
Professional fees 82,608   277,282  
Marketing expenses    
General and administrative expenses 204,958   382,857  
Total operating expenses 649,395   1,737,479  
Operating Income (Loss) (207,704)   (466,432)  
Interest (expense) (9,992)   (15,805)  
Net Income (Loss) Before Taxes (217,696)   (482,237)  
Deferred income tax benefit    
Net Income (Loss) (217,696)   (482,237)  
Net income (loss) attributable to noncontrolling interests 8,955   6,439  
Net Income (loss) attributable to Immudyne, Inc. $ (226,651)   $ (488,676)  
Basic and diluted (loss) per share attributable to Immudyne, Inc. $ (0.01)   $ (0.02)  
Average number of common shares outstanding        
Basic 34,427,087   31,917,873  
Diluted $ 34,427,087   $ 31,917,873  
Adjustment [Member]        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Cost of sales $ (554,536)   $ (1,713,337)  
Operating expenses        
Marketing expenses $ 554,536   $ 1,713,337